22 of the 40 PI-experienced patients (55%) had cirrhosis.
in the arms of ELECTRON trial in pts with cirrhosis the same GILD combo had 80% and 89% SVR with and without ribavirin, respectively. now the numbers are small with 10 and 9 patients, respectively, but does suggest GILD will likely need at least 12 weeks and ribavirin in these patients
note both are similar pt populations gen-1 w compensated cirrhosis, so this is more a small numbers issue than anything else. I think this highlights how extrapolating from small phase 2 studies can lead to surprising results, just like GILD found out in genotype 3s after phase 3
Market Data 
Markets 
AI
